Trial Profile
Alendronate to Prevent Perimenopausal Transition Bone Loss
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Alendronic acid (Primary)
- Indications Menopause; Osteoporosis
- Focus Therapeutic Use
- 05 Jan 2010 Status changed from recruiting to completed.
- 05 Jan 2010 Results published in Fertility and Sterility.
- 05 Jan 2010 Primary endpoint 'Lumbar spine bone mineral density' has been met.